drugset / Trial / NCT01270256

NasoNeb Delivery of an Intranasal Steroid

NCT01270256

Phase 4 Completed 41 enrolled University of Chicago MedInvent, LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).

Timeline

Start
2011-01
Primary completion
2012-07
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 0.25 mg Intranasal